CONMED (CNMD) Stock Forecast, Price Target & Predictions
CNMD Stock Forecast
CONMED stock forecast is as follows: an average price target of $101.00 (represents a 33.95% upside from CNMD’s last price of $75.40) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.
CNMD Price Target
The average price target for CONMED (CNMD) is $101.00 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $107.00 to $95.00. This represents a potential 33.95% upside from CNMD's last price of $75.40.
CNMD Analyst Ratings
According to 4 Wall Street analysts, CONMED's rating consensus is 'Buy'. The analyst rating breakdown for CNMD stock is 0 'Strong Buy' (0.00%), 4 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
CONMED Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Apr 25, 2024 | Matt O\'Brien | Piper Sandler | $95.00 | $64.34 | 47.65% | 25.99% |
| Apr 25, 2024 | Mike Matson | Needham | $107.00 | $70.01 | 52.84% | 41.91% |
| Oct 26, 2022 | Matt O'Brien | Piper Sandler | $108.00 | $83.39 | 29.51% | 43.24% |
The latest CONMED stock forecast, released on Apr 25, 2024 by Matt O\'Brien from Piper Sandler, set a price target of $95.00, which represents a 47.65% increase from the stock price at the time of the forecast ($64.34), and a 25.99% increase from CNMD last price ($75.40).
CONMED Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 2 |
| Avg Price Target | - | - | $101.00 |
| Last Closing Price | $75.40 | $75.40 | $75.40 |
| Upside/Downside | -100.00% | -100.00% | 33.95% |
In the current month, the average price target of CONMED stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to CONMED's last price of $75.40. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 01, 2024 | Wells Fargo | Buy | Buy | Hold |
| Apr 25, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Apr 25, 2024 | Needham | Buy | Buy | Hold |
| Feb 01, 2024 | Wells Fargo | Equal-Weight | Equal-Weight | Hold |
| Feb 01, 2024 | Needham | Buy | Buy | Hold |
| Apr 27, 2023 | Piper Sandler | Overweight | Overweight | Hold |
| Apr 27, 2023 | Needham | Buy | Buy | Hold |
| Apr 27, 2023 | Wells Fargo | Equal-Weight | Equal-Weight | Hold |
| Mar 27, 2023 | KeyBanc | - | Overweight | Upgrade |
| Feb 02, 2023 | Piper Sandler | Overweight | Overweight | Hold |
CONMED's last stock rating was published by Wells Fargo on Aug 01, 2024. The company gave CNMD a "Buy" rating, the same as its previous rate.
CONMED Financial Forecast
CONMED Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | $327.05M | - | $317.65M | $295.47M | $250.87M | $275.09M | - | $242.33M | $273.97M | $248.83M | $255.16M | $232.68M | $252.83M | $237.84M | $157.78M | $214.01M | $264.87M | $233.59M |
| Avg Forecast | $397.71M | $368.68M | $384.12M | $359.50M | $377.43M | $346.58M | $358.07M | $335.25M | $345.37M | $318.74M | $334.39M | $306.75M | $332.21M | $301.42M | $306.15M | $266.63M | $302.48M | $280.83M | $275.75M | $235.77M | $275.82M | $255.23M | $248.47M | $216.77M | $262.90M | $205.92M | $126.59M | $214.85M | $264.83M | $228.20M |
| High Forecast | $399.37M | $370.21M | $385.72M | $361.00M | $379.01M | $348.02M | $359.57M | $336.65M | $346.81M | $319.82M | $335.79M | $308.03M | $335.16M | $303.70M | $307.43M | $267.74M | $303.74M | $282.00M | $275.75M | $240.00M | $280.76M | $259.80M | $252.92M | $220.65M | $267.61M | $209.61M | $128.86M | $218.69M | $269.57M | $232.29M |
| Low Forecast | $395.68M | $366.79M | $382.16M | $357.66M | $375.50M | $344.80M | $356.24M | $333.54M | $343.60M | $317.76M | $332.68M | $305.18M | $331.27M | $297.71M | $304.59M | $265.27M | $300.93M | $279.39M | $275.75M | $233.76M | $273.47M | $253.05M | $246.35M | $214.92M | $260.66M | $204.17M | $125.51M | $213.01M | $262.57M | $226.25M |
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 3 | 6 | 8 | 5 | 4 | 4 | 3 | 5 | 3 | 6 | 4 | 6 | 3 | 3 | 3 | 3 | 3 | 2 | 3 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.98% | - | 1.04% | 1.11% | 0.83% | 0.98% | - | 1.03% | 0.99% | 0.97% | 1.03% | 1.07% | 0.96% | 1.15% | 1.25% | 1.00% | 1.00% | 1.02% |
CONMED's average Quarter revenue forecast for Mar 24 based on 3 analysts is $306.75M, with a low forecast of $305.18M, and a high forecast of $308.03M. CNMD's average Quarter revenue forecast represents a -6.21% decrease compared to the company's last Quarter revenue of $327.05M (Dec 23).
CONMED EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 3 | 6 | 8 | 5 | 4 | 4 | 3 | 5 | 3 | 6 | 4 | 6 | 3 | 3 | 3 | 3 | 3 | 2 | 3 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $60.97M | - | $27.42M | $12.70M | $-1.09M | $24.25M | - | $22.44M | $54.69M | $42.79M | $43.49M | $38.36M | $42.65M | $47.26M | $-3.13M | $31.50M | $44.28M | $40.17M |
| Avg Forecast | $27.40M | $25.40M | $26.46M | $24.77M | $26.00M | $23.88M | $24.67M | $23.10M | $23.79M | $21.96M | $23.04M | $47.60M | $22.89M | $20.77M | $21.09M | $43.27M | $20.84M | $43.93M | $19.00M | $34.21M | $52.57M | $39.94M | $37.18M | $23.97M | $38.16M | $77.67M | $-5.43M | $28.08M | $43.79M | $35.87M |
| High Forecast | $27.51M | $25.51M | $26.57M | $24.87M | $26.11M | $23.98M | $24.77M | $23.19M | $23.89M | $22.03M | $23.13M | $57.12M | $23.09M | $20.92M | $21.18M | $51.93M | $20.93M | $52.72M | $19.00M | $41.05M | $63.08M | $47.93M | $44.61M | $28.77M | $45.79M | $93.20M | $-4.34M | $33.70M | $52.54M | $43.04M |
| Low Forecast | $27.26M | $25.27M | $26.33M | $24.64M | $25.87M | $23.75M | $24.54M | $22.98M | $23.67M | $21.89M | $22.92M | $38.08M | $22.82M | $20.51M | $20.98M | $34.62M | $20.73M | $35.15M | $19.00M | $27.37M | $42.06M | $31.95M | $29.74M | $19.18M | $30.53M | $62.13M | $-6.51M | $22.46M | $35.03M | $28.69M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 2.66% | - | 1.30% | 0.29% | -0.05% | 0.55% | - | 0.66% | 1.04% | 1.07% | 1.17% | 1.60% | 1.12% | 0.61% | 0.58% | 1.12% | 1.01% | 1.12% |
3 analysts predict CNMD's average Quarter EBITDA for Mar 24 to be $47.60M, with a high of $57.12M and a low of $38.08M. This is -21.93% lower than CONMED's previous annual EBITDA (Dec 23) of $60.97M.
CONMED Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 3 | 6 | 8 | 5 | 4 | 4 | 3 | 5 | 3 | 6 | 4 | 6 | 3 | 3 | 3 | 3 | 3 | 2 | 3 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $33.07M | - | $13.73M | $1.82M | $26.58M | $46.15M | - | $14.97M | $24.44M | $14.95M | $13.29M | $9.86M | $24.14M | $6.85M | $-27.40M | $5.93M | $14.93M | $6.97M |
| Avg Forecast | $53.14M | $43.57M | $43.82M | $37.03M | $46.39M | $38.84M | $38.44M | $31.98M | $38.06M | $30.77M | $28.31M | $18.15M | $34.57M | $26.09M | $24.70M | $16.50M | $28.13M | $15.35M | $23.60M | $13.04M | $23.49M | $13.95M | $11.36M | $6.16M | $21.60M | $11.26M | $-47.50M | $5.28M | $14.77M | $6.22M |
| High Forecast | $53.43M | $43.80M | $44.06M | $37.23M | $46.64M | $39.05M | $38.64M | $32.15M | $38.26M | $31.08M | $28.46M | $21.78M | $34.88M | $26.40M | $24.83M | $19.80M | $28.28M | $18.42M | $23.60M | $15.65M | $28.19M | $16.74M | $13.63M | $7.39M | $25.92M | $13.51M | $-38.00M | $6.34M | $17.72M | $7.47M |
| Low Forecast | $52.79M | $43.28M | $43.53M | $36.78M | $46.08M | $38.58M | $38.18M | $31.76M | $37.80M | $30.45M | $28.12M | $14.52M | $34.26M | $25.78M | $24.53M | $13.20M | $27.94M | $12.28M | $23.60M | $10.43M | $18.80M | $11.16M | $9.09M | $4.93M | $17.28M | $9.01M | $-57.00M | $4.23M | $11.81M | $4.98M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.96% | - | 0.56% | 0.11% | 0.95% | 3.01% | - | 1.15% | 1.04% | 1.07% | 1.17% | 1.60% | 1.12% | 0.61% | 0.58% | 1.12% | 1.01% | 1.12% |
CONMED's average Quarter net income forecast for Mar 24 is $18.15M, with a range of $14.52M to $21.78M. CNMD's average Quarter net income forecast represents a -45.12% decrease compared to the company's last Quarter net income of $33.07M (Dec 23).
CONMED SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 3 | 6 | 8 | 5 | 4 | 4 | 3 | 5 | 3 | 6 | 4 | 6 | 3 | 3 | 3 | 3 | 3 | 2 | 3 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $127.33M | - | $129.70M | $130.08M | $120.74M | $114.60M | - | $102.88M | $107.28M | $104.74M | $104.40M | $98.34M | $99.10M | $94.38M | $84.47M | $95.87M | $102.00M | $98.19M |
| Avg Forecast | $164.45M | $152.45M | $158.83M | $148.65M | $156.07M | $143.31M | $148.06M | $138.63M | $142.81M | $131.80M | $138.27M | $124.68M | $137.37M | $124.64M | $126.59M | $113.35M | $125.08M | $107.53M | $114.02M | $89.60M | $103.11M | $97.75M | $89.24M | $61.46M | $88.66M | $155.11M | $52.34M | $85.45M | $100.85M | $87.67M |
| High Forecast | $165.14M | $153.08M | $159.50M | $149.27M | $156.72M | $143.91M | $148.68M | $139.21M | $143.41M | $132.24M | $138.85M | $149.62M | $138.59M | $125.58M | $127.12M | $136.01M | $125.60M | $129.03M | $114.02M | $107.52M | $123.73M | $117.30M | $107.09M | $73.75M | $106.40M | $186.13M | $53.28M | $102.54M | $121.03M | $105.20M |
| Low Forecast | $163.61M | $151.67M | $158.02M | $147.89M | $155.27M | $142.58M | $147.30M | $137.92M | $142.08M | $131.39M | $137.56M | $99.74M | $136.98M | $123.10M | $125.95M | $90.68M | $124.44M | $86.02M | $114.02M | $71.68M | $82.49M | $78.20M | $71.40M | $49.17M | $70.93M | $124.09M | $51.90M | $68.36M | $80.68M | $70.13M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.93% | - | 1.02% | 1.15% | 0.97% | 1.07% | - | 1.15% | 1.04% | 1.07% | 1.17% | 1.60% | 1.12% | 0.61% | 1.61% | 1.12% | 1.01% | 1.12% |
CONMED's average Quarter SG&A projection for Mar 24 is $124.68M, based on 3 Wall Street analysts, with a range of $99.74M to $149.62M. The forecast indicates a -2.08% fall compared to CNMD last annual SG&A of $127.33M (Dec 23).
CONMED EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 3 | 6 | 8 | 5 | 4 | 4 | 3 | 5 | 3 | 6 | 4 | 6 | 3 | 3 | 3 | 3 | 3 | 2 | 3 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | $1.05 | - | $0.45 | $0.06 | $0.87 | $1.51 | - | $0.51 | $0.83 | $0.51 | $0.46 | $0.34 | $0.84 | $0.24 | $-0.96 | $0.21 | $0.53 | $0.25 |
| Avg Forecast | $1.71 | $1.40 | $1.41 | $1.19 | $1.49 | $1.25 | $1.24 | $1.03 | $1.22 | $0.99 | $0.91 | $0.74 | $1.11 | $0.84 | $0.79 | $0.60 | $0.90 | $0.75 | $0.75 | $0.62 | $1.03 | $0.75 | $0.62 | $0.44 | $0.77 | $0.23 | $-0.99 | $0.46 | $0.89 | $0.56 |
| High Forecast | $1.72 | $1.41 | $1.42 | $1.20 | $1.50 | $1.26 | $1.24 | $1.03 | $1.23 | $1.00 | $0.92 | $0.74 | $1.12 | $0.85 | $0.80 | $0.60 | $0.91 | $0.76 | $0.75 | $0.63 | $1.05 | $0.77 | $0.63 | $0.45 | $0.78 | $0.23 | $-0.98 | $0.47 | $0.91 | $0.57 |
| Low Forecast | $1.70 | $1.39 | $1.40 | $1.18 | $1.48 | $1.24 | $1.23 | $1.02 | $1.22 | $0.98 | $0.90 | $0.73 | $1.10 | $0.83 | $0.79 | $0.59 | $0.90 | $0.75 | $0.75 | $0.61 | $1.02 | $0.74 | $0.61 | $0.43 | $0.76 | $0.23 | $-1.02 | $0.46 | $0.88 | $0.56 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.94% | - | 0.57% | 0.10% | 0.96% | 2.01% | - | 0.82% | 0.81% | 0.68% | 0.74% | 0.78% | 1.10% | 1.05% | 0.97% | 0.45% | 0.60% | 0.45% |
According to 3 Wall Street analysts, CONMED's projected average Quarter EPS for Mar 24 is $0.74, with a low estimate of $0.73 and a high estimate of $0.74. This represents a -29.73% decrease compared to CNMD previous annual EPS of $1.05 (Dec 23).
CONMED Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| ATEC | Alphatec | $5.59 | $16.64 | 197.67% | Buy |
| IRTC | iRhythm | $76.61 | $144.20 | 88.23% | Buy |
| OFIX | Orthofix Medical | $16.76 | $31.00 | 84.96% | - |
| SGHT | Sight Sciences | $6.95 | $10.33 | 48.63% | Hold |
| LUNG | Pulmonx | $8.31 | $12.25 | 47.41% | Buy |
| LIVN | LivaNova | $48.53 | $71.25 | 46.82% | Buy |
| CNMD | CONMED | $75.40 | $101.00 | 33.95% | Buy |
| SIBN | SI-BONE | $15.73 | $20.00 | 27.15% | Buy |
| KIDS | OrthoPediatrics | $32.28 | $40.80 | 26.39% | Buy |
| GMED | Globus Medical | $69.75 | $79.54 | 14.04% | Buy |
| ITGR | Integer | $126.78 | $131.00 | 3.33% | Buy |
| SRDX | Surmodics | $39.36 | $39.50 | 0.36% | Buy |
| STE | STERIS | $244.83 | $245.00 | 0.07% | Buy |
| GKOS | Glaukos | $126.28 | $101.56 | -19.58% | Buy |
CNMD Forecast FAQ
Is CONMED a good buy?
Yes, according to 4 Wall Street analysts, CONMED (CNMD) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 100.00% of CNMD's total ratings.
What is CNMD's price target?
CONMED (CNMD) average price target is $101 with a range of $95 to $107, implying a 33.95% from its last price of $75.4. The data is based on 4 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will CONMED stock go up soon?
According to Wall Street analysts' prediction for CNMD stock, the company can go up by 33.95% (from the last price of $75.4 to the average price target of $101), up by 41.91% based on the highest stock price target, and up by 25.99% based on the lowest stock price target.
Can CONMED stock reach $110?
CNMD's average twelve months analyst stock price target of $101 does not support the claim that CONMED can reach $110 in the near future.
What are CONMED's analysts' financial forecasts?
CONMED's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $1.42B (high $1.42B, low $1.41B), average EBITDA is $97.64M (high $98.05M, low $97.14M), average net income is $155.65M (high $156.49M, low $154.61M), average SG&A $586.07M (high $588.51M, low $583.07M), and average EPS is $5 (high $5.03, low $4.97). CNMD's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $1.51B (high $1.52B, low $1.5B), average EBITDA is $104.03M (high $104.46M, low $103.5M), average net income is $177.56M (high $178.53M, low $176.38M), average SG&A $624.38M (high $626.99M, low $621.19M), and average EPS is $5.71 (high $5.74, low $5.67).
Did the CNMD's actual financial results beat the analysts' financial forecasts?
Based on CONMED's last annual report (Dec 2023), the company's revenue was $1.24B, beating the average analysts forecast of $1.21B by 3.18%. Apple's EBITDA was $209.09M, beating the average prediction of $108.02M by 93.58%. The company's net income was $64.46M, missing the average estimation of $101.85M by -36.71%. Apple's SG&A was $497.08M, missing the average forecast of $501.94M by -0.97%. Lastly, the company's EPS was $2.04, missing the average prediction of $3.34 by -38.95%. In terms of the last quarterly report (Dec 2023), CONMED's revenue was $327.04M, missing the average analysts' forecast of $332.21M by -1.55%. The company's EBITDA was $60.97M, beating the average prediction of $22.89M by 166.41%. CONMED's net income was $33.07M, missing the average estimation of $34.57M by -4.33%. The company's SG&A was $127.33M, missing the average forecast of $137.37M by -7.31%. Lastly, the company's EPS was $1.05, missing the average prediction of $1.11 by -5.51%